STOCK TITAN
  1. Home
  2. Sec-filings
  3. BVS
  4. [8-K] Bioventus Inc. Reports Material Event

CMS reimbursement shifts leave Bioventus (NASDAQ: BVS) 2026 guidance intact

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Bioventus Inc. reports U.S. regulatory and reimbursement changes affecting its Exogen Ultrasound Bone Healing System but keeps its 2026 outlook unchanged. The FDA issued a final order on April 16, 2026 reclassifying non-invasive bone growth stimulators, including Exogen, from higher-risk Class III to Class II devices.

Following this, CMS updated billing requirements and the Medicare fee schedule for non-invasive bone growth stimulators billed under HCPCS codes E0747, E0748 and E0760 for dates of service on or after May 18, 2026. Bioventus currently does not expect the revised reimbursement rates for Exogen to have a material impact on fiscal 2026 results and is reiterating its financial guidance, while continuing to evaluate potential longer-term effects of any current or future CMS actions.

Positive

  • None.

Negative

  • None.

Insights

FDA down‑classification and CMS reimbursement tweaks look neutral near term.

The FDA’s move from Class III to Class II generally implies a lower regulatory burden for non-invasive bone growth stimulators, including Bioventus’ Exogen device. CMS has simultaneously adjusted billing rules and Medicare fee schedules for the relevant HCPCS codes.

Bioventus states it does not expect these reimbursement changes to materially affect fiscal 2026 results and is reiterating 2026 guidance, framing the update as neutral in the near term. Longer-term impact depends on how future CMS actions evolve and how Exogen utilization and payer mix respond.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
FDA reclassification date April 16, 2026 Final order reclassifying non-invasive bone growth stimulators to Class II
CMS effective service date May 18, 2026 Medicare billing and fee schedule changes for HCPCS E0747, E0748, E0760
2026 financial guidance Reiterated Company does not expect material 2026 impact from Exogen reimbursement changes
Regulation FD Disclosure regulatory
"Item 7.01. Regulation FD Disclosure."
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
final order reclassifying regulatory
"the FDA issued a final order reclassifying non-invasive bone growth stimulators"
Class II devices regulatory
"from Class III to Class II devices"
HCPCS codes financial
"billed under HCPCS codes E0747, E0748, and E0760"
Medicare fee schedule financial
"updated certain billing requirements and the Medicare fee schedule applicable"
forward-looking statements regulatory
"contains forward-looking statements within the meaning of Section 27A"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

What regulatory change did Bioventus (BVS) disclose for its Exogen device?
Bioventus disclosed that on April 16, 2026, the FDA issued a final order reclassifying non-invasive bone growth stimulators, including its Exogen system, from Class III to Class II devices. This shifts Exogen into a lower-risk device category under FDA regulation.

How did CMS change reimbursement affecting Bioventus (BVS) Exogen sales?
CMS updated billing requirements and the Medicare fee schedule for non-invasive bone growth stimulators billed under HCPCS codes E0747, E0748 and E0760 for dates of service on or after May 18, 2026. These changes directly affect how Exogen-related claims are billed and reimbursed by Medicare.

Does Bioventus (BVS) expect CMS reimbursement changes to impact 2026 results?
Bioventus currently does not expect the revised Medicare reimbursement rates for its Exogen device to have a material impact on financial results for fiscal year 2026. Based on available information, the company is maintaining its previously issued 2026 financial guidance despite the CMS updates.

Is Bioventus (BVS) changing its 2026 financial guidance after FDA and CMS actions?
No. Bioventus is reiterating its previously issued financial guidance for 2026. The company states that, based on currently available information, the reimbursement changes for Exogen are not expected to be material to its fiscal 2026 financial performance.

What future risks does Bioventus (BVS) highlight regarding CMS decisions?
Bioventus notes that it will continue evaluating the potential long-term impact of current and any future CMS actions. It cautions that further changes to Medicare reimbursement rates for Exogen could eventually require revisions to its financial outlook beyond the current 2026 guidance.

Which Bioventus (BVS) product is directly affected by these regulatory changes?
The changes directly affect Bioventus’ Exogen Ultrasound Bone Healing System, a non-invasive bone growth stimulator. FDA reclassification and CMS reimbursement updates both specifically reference non-invasive bone growth stimulators, a category that explicitly includes the Exogen device.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001665988FALSE00016659882026-05-212026-05-21

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 21, 2026
 
Bioventus Inc.
(Exact name of registrant as specified in charter)
 
Delaware
 
001-37844
 
81-0980861
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification Number)
4721 Emperor Boulevard, Suite 100
Durham, North Carolina 27703
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (919) 474-6700
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17     CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Class A common Stock, $0.001 par value per share
 
BVS
 
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☒


Item 7.01. Regulation FD Disclosure.
On April 16, 2026, the U.S. Food and Drug Administration (“FDA”) issued a final order reclassifying non-invasive bone growth stimulators, including the Company’s Exogen® Ultrasound Bone Healing System, from Class III to Class II devices. In connection with this reclassification, the Centers for Medicare & Medicaid Services (“CMS”) has updated certain billing requirements and the Medicare fee schedule applicable to non-invasive bone growth stimulators billed under HCPCS codes E0747, E0748, and E0760 for dates of service on or after May 18, 2026.
Based on currently available information, the Company does not presently expect the changes to the reimbursement rates applicable to its Exogen device to have a material impact on its financial results for fiscal year 2026. Accordingly, the Company is reiterating its previously issued financial guidance for 2026.
The Company will continue to evaluate the potential long-term impact of current and any future CMS actions. Potential further changes by CMS to the applicable Medicare reimbursement rates for the Exogen device could require the Company to revise its financial outlook.
Legal Notice Regarding Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements including the implementation of the revised reimbursement rates and rules and other risks and uncertainties affecting the Company’s business, or the timing of any of the foregoing. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause our actual results to differ materially from those contemplated in this Current Report on Form 8-K include, but are not limited to the potential long-term impact of the FDA’s down classification of bone growth stimulators and any current or future CMS actions, as well as the risks identified in our Annual Report on Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in Bioventus’ other filings with the Securities and Exchange Commission (the “SEC”) which are accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Bioventus’ website at https://ir.bioventus.com. Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ materially from those set forth in the forward-looking statements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
BIOVENTUS INC.
Date: May 21, 2026
By:
/s/ Anthony D’Adamio
Anthony D’Adamio
Senior Vice President and General Counsel

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Other Documents